GSK stock price forecast: £2,138–£2,200 range as GSK trades sideways

Traders Union
All News
Financial News
GSK dips 0.82% today to GBX2172.00

Highlights

GSK finalized its $950 million acquisition of 35Pharma and pulmonary hypertension candidate HS235, adding to its chronic disease pipeline.
The company integrated enhanced environmental performance goals into its 2025 Annual Report via its Responsible Business framework despite ongoing selling pressure.
GSK trades in a strong bull trend above key technical support, though short-term overbought signals suggest a high-probability consolidation between GBX 2,138 and GBX 2,200.

Portfolio expansion and ESG focus as shares face selling pressure

GSK completed the $950 million acquisition of 35Pharma Inc. and its pulmonary hypertension drug HS235. The company stated that HS235 has been added to GSK's respiratory, immunology, and inflammation pipeline, expanding its portfolio in chronic disease therapeutics. GSK also reinforced its sustainability approach in the 2025 Annual Report by integrating environmental performance through its 'Responsible Business' framework, though price action has remained under broader selling pressure.

Divergence emerges as overbought signals clash with session weakness

Momentum signals are generally positive, with MACD and ADX both reflecting underlying bullishness, though ADX D1 indicates a neutral trend strength. RSI (65.72), Stoch RSI (100.00), and CCI (122.61) all point to overbought conditions, suggesting stretched upside potential, while BBP (73.09) confirms ongoing buyer dominance. The AO also supports the prevailing uptrend. Today’s session opened slightly above the previous close (no significant gap), but the price has since edged lower, slipping 0.82%. The current price is near the low end of the day’s range, indicating moderate intraday volatility and prevailing pressure after the open. This daily loss and weakness toward the session’s low contrast with the overall bullish momentum, highlighting a divergence between short-term price action and the broader technical backdrop.

High probability of consolidation as breakout and reversal levels defined

For the next five trading days, GSK is expected to remain within the typical volatility band of GBX 2,138 to GBX 2,200. The probability of further price gains is very high (over 80%), with declines considered unlikely. The baseline scenario anticipates consolidation within this projected corridor. A move above GBX 2,200 could ignite renewed upside momentum, while a drop below immediate support at GBX 2,051 may indicate a corrective phase.

Anton Kharitonov, analyst at Traders Union, notes that GSK remains in a technically strong position despite recent intraday weakness. He sees broad bullish momentum confirmed but remains cautious given overbought readings and recent selling pressure. The analyst believes price will likely consolidate within the GBX 2,138–2,200 band unless immediate support at GBX 2,051 breaks. "Until we see a decisive move above GBX 2,200 or a failure at GBX 2,051, my approach stays defensive and scenario-based."

Earlier, analysts noted that GSK was exhibiting persistent bullish momentum despite indications of short-term overbought conditions and the potential for consolidation. The latest developments—highlighted by a major acquisition and continued technical strength even amid brief intraday weakness—reinforce the bullish outlook, with a breakout above GBX 2,200 now the pivotal level that could catalyze further upside.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.